Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $9.00

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.50.

CTMX has been the subject of a number of research reports. Oppenheimer restated an “outperform” rating and set a $12.00 target price on shares of CytomX Therapeutics in a research report on Monday. Wedbush boosted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $7.00 to $12.00 in a report on Monday. Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research report on Monday, March 9th. Finally, Cantor Fitzgerald lifted their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th.

CytomX Therapeutics Trading Down 19.3%

NASDAQ CTMX opened at $5.45 on Wednesday. The stock’s 50 day moving average is $5.26 and its 200 day moving average is $4.09. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21. The stock has a market cap of $923.39 million, a PE ratio of -136.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative return on equity of 20.65% and a negative net margin of 22.79%. On average, analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 Varseta‑M expansion showed meaningful activity in heavily pretreated metastatic colorectal cancer (32% response rate at 10 mg/kg Q3W; estimated PFS ~7.1 months) with a manageable safety profile and planned FDA discussions to align on potential registrational trial — this is the primary catalyst for the earlier rally. Read More.
• Positive Sentiment: Multiple firms upgraded or raised price targets after the data (examples: Wedbush, HC Wainwright, JPMorgan noted higher PTs and upgraded ratings), which amplified buying interest and momentum. Read More.
• Neutral Sentiment: Company released its Q4 materials, slide deck and hosted an earnings call discussing the clinical progress and next‑steps (including combination studies and timelines) — useful context for longer‑term investors assessing pathway to a registrational study. Read More.
• Negative Sentiment: CytomX filed for an underwritten public offering to raise $250M (common stock and pre‑funded warrants) — a near‑term dilution risk that likely pressured the stock after the initial data‑driven surge. Read More.
• Negative Sentiment: Q4 results missed expectations (EPS and revenue; EPS -$0.22 vs. est. -$0.08; revenue ~$0.66M vs. est. ~$7.33M), which reinforces near‑term funding needs and contributed to selling pressure. Read More.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics in the 1st quarter worth approximately $39,000. Woodline Partners LP bought a new position in shares of CytomX Therapeutics during the 1st quarter valued at approximately $1,054,000. Geode Capital Management LLC boosted its position in shares of CytomX Therapeutics by 103.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after acquiring an additional 887,218 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of CytomX Therapeutics in the second quarter valued at $13,096,000. Finally, XTX Topco Ltd purchased a new position in shares of CytomX Therapeutics in the second quarter valued at $277,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.